Hundreds of children and adults with rare forms of cystic fibrosis in England will be able to access “life-changing” new ‘triple-combination’ therapy for the very first time, the NHS has announced.

Merck MRK recently intensified its acquisition strategy, actively pursuing deals to enhance its development pipeline and broaden its product portfolio. To build its long-term portfolio, the company ...

Most European travellers heading to sub-tropical regions know to make sure they're up to date on their vaccinations. While ...

The amended product information will provide more specific detail on encephalitis as a known adverse reaction to ...

Clozapine blood monitoring can now be reduced to every 12 weeks after 1 year of treatment, and annually after 2 years, in patients without neutropenia.

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa ...